Abstract: The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.

Abstract: A disinfectant formulation comprising a polymer binder and a biocidal compound, having a residual biocidal property. The polymer binder is an oxazoline homopolymer or an extended or a modified polymer based on an oxazoline homopolymer. The disinfectant formulation may further comprise a surfactant, a pH adjusting agent, and a solvent.

Abstract: A disinfectant formulation is provided imparting a residual biocidal property. The disinfectant formulation is used to treat a surface to impart a film having a capacity to quickly kill bacteria and other germs for at least 24 hours after deposit of the film on a treated surface. The disinfectant formulation comprises a polymer binder, wherein the polymer binder is an oxazoline homopolymer or an extended or a modified polymer based on an oxazoline homopolymer, and a biocidal compound. The disinfectant formulation further comprises a carrier. An article having the disinfectant formulation is provided as well as methods of making, using and applying the disinfectant formulation.

Abstract: A tablet composition is provided that comprises a core encapsulated by a coating. The core comprises at least one metal chlorite dispersed in a composite matrix and an effervescent agent, and the coating comprises an acid source. The tablet composition can producing chlorine dioxide upon contacting with water, where the chlorine dioxide is retained in the water for an extended period to provide prolonged disinfecting effects. Compositions in powder form are also provided.

Abstract: The present invention relates to cosmetic and skin care compositions comprising magnetosomes. The invention also relates to methods for the treatment of diseases associated with increased proliferation or accumulation of differentiating keratinocytes.

Abstract: A pharmaceutical composition is described that is suitable for delivery from a pressurised container. The composition is preferably free of polar excipients and comprises: (a) a propellant component that consists essentially of 1,1-difluoroethane (R-152a); (b) a surfactant component that comprises at least one surfactant compound other than oleic acid; and (c) a drug component that consists of salbutamol sulphate. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).

Abstract: A disinfectant formulation comprising a poly(2-ethyl-2-oxazoline) and a quaternary ammonium compound or combination of quaternary ammonium compounds is provided. A wipe having a residual biocidal property is also provided. The wipe formulation comprises a substrate comprised of a fibrous material, and the formulation present on or in the substrate. The formulation comprises a poly(2-ethyl-2-oxazoline), a quaternary ammonium compound or combination of quaternary ammonium compounds, a surfactant, water, and an optional fragrance.

Abstract: Methods of delaying the onset of an infection or preventing an infection caused by a microbial organism in an internal cavity of a subject are provided. Methods of killing or inactivating microorganisms in at least a portion of the urethra of a subject are provided.

Abstract: A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.

Abstract: Fungal diseases and resulting mycotoxins are reduced or eliminated from plant tissues during crop growth or post-harvest during storage by treatment with an aqueous spray solution prepared from a fungicide composition of a bicarbonate salt containing a surfactant system to reduce the surface tension and contact angle of the spray solution on the plant surface thereby controlling the crystal size of the bicarbonate and re-distribution and adherence of the crystals to the crop vegetation and/or grains.

Abstract: A method for preparing a product for treating the skin and mucous membranes comprises the steps of making available a suitable quantity of trichloroacetic acid, making available a suitable quantity of hydrogen peroxide, making a first mixture of the trichloroacetic acid and the hydrogen peroxide, making available a determinate quantity of the basic compound able to achieve a buffer effect of the trichloroacetic acid comprised in the first mixture, and adding the basic compound.

Abstract: The present invention provides an intermediate composition enabling to prepare easily and steadily an ?-gel-containing O/W emulsion cosmetic that has a very small viscosity change over time and is excellent in emulsion stability, without using a cooling device that has a heavy burden on cost and the environment, and a production method thereof. An ?-gel intermediate composition consisting of (A) 20 to 80 mass % of a mixture containing one or more higher alcohols having 16 or more carbon atoms and a nonionic surfactant with an HLB value of 7 to 17 in the mole ratio of 3:2 to 5:1, and (B) 20 to 80 mass % of a mixture containing one or more water-soluble solvents having the IOB value of 1.5 to 3.5 and water in the mass ratio of 4:6 to 8:2, and wherein the composition is a liquid consisting of a bicontinuous microemulsion phase or a lamellar liquid crystal-dispersed bicontinuous microemulsion phase at 50 to 80° C. and a solid at room temperature.

Abstract: The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding polymer to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.

Abstract: An anti-neoplastic stable pharmaceutical composition comprising Temozolomide, high substituted polysaccharide phosphate in salt form, and high substituted polysaccharide phosphate in acidic form, in particular in a weight ratio of from 5 to 20% Temozolomide to 30 to 80% of polysaccharide in salt form, the reminder up to 100% being polysaccharide in acidic form. The level of 5-aminomidazole-4-carboxamide is below 0.5% by weight of Temozolomide in both the composition and the formulation disclosed. Also disclosed is a hydrogel for intrathecal administration obtainable by contacting the composition with sterile water, a method of manufacture of the composition and uses of the composition and the gel.

Abstract: A method and system for addressing the avoidance of migraines, cluster headaches and dizziness by adjusting an individual's microbiome, and in particular, to the provision of beneficial oral and gut microbes at particular times to enhance a person's oral health, including through the use of oral strips that adhere to surfaces in the oral cavity and that include at least one of xylitol, Lachnospira, Veillonella, Faecalibacterium and/or Rothia bacteria, including bacteria transformed via a CR/SPR system.

Abstract: A cationic hair care emulsion is providing including: a cationic surfactant; water, wherein the water forms a continuous phase; and an internal phase, wherein the internal phase comprises: a cosmetically acceptable hydrocarbon oil; and a polyolefin blend, comprising: a high density polyolefin having a density >0.90 g/cm3; and a low density polyolefin having a density of ?0.90 g/cm3; wherein the polyolefin blend has an average melt index of >7 as measured according to ASTM D 1238.

Abstract: A method and system to prevent sore throat infections in humans includes the administration of an active ingredient to a site on the mucus membranes of the throat of a human that inhibits adherence and promotes desorption of S. pyogenes to soft tissue surfaces, such as the pharyngeal and oral mucosa of a human. A mucoadhesive strip having a surface topography that resists bioadhesion of undesired bacteria that are typically present in a human's mouth is preferably employed and that has one or more encapsulated agents selected from the group consisting of an antibiotic; lactic acid bacteria; S. pyogenes modified by a CRISPR-Cas system to reduce one or more virulence factors; and a breath mint solution.

Abstract: This invention relates to abuse-deterrent pharmaceutical compositions and dosage forms and manufacturing processes thereof, the compositions comprising an agonist and antagonist that are difficult to separate visually, physically, or chemically. The compositions comprise a tacky amorphous polymer and a crystalline polymer curing agent for the amorphous polymer such that the agonist is releasable and the antagonist is non-releasable unless the dosage forms are tampered with. The non-extractable dosage forms reduce the potential for prescription drug abuse.

Abstract: This invention relates to an oil composition, preferably obtained from a copepod, and the use thereof to reduce accumulation of visceral fat and counteract impairment of heart function caused by obesity inducing Western diets. The oil composition of the present invention can thus be used to reduce abdominal obesity and improve glucose tolerance and thus to reduce the risk of obesity related diseases such as but not limited to type 2 diabetes or cardiovascular disease, or to prevent or treat such diseases.

Abstract: A method performing a Friedel-Crafts alkylation reaction between a dichloroalkane and an alkylbenzene produces a compound for hair regrowth. The inventive subject matter further includes incorporation of such compounds in topical formulations with suitable carriers. The resulting topical formulations may be employed in methods of stimulating hair regrowth.